CLINICAL ROLE -
Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD
Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.
Read More
Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps
The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.
Clinical Efficacy of Non-Statin Treatment Options in ASCVD
Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.
Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD
Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.
Key Barriers in Implementing Guideline-Directed Cholesterol Treatment
Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.
Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines
The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.
Impact of Medicare Part D on Utilization and Expenditures
Examination of pharmacy behaviors before and after implementation indicated that restrictions in pharmacy benefits may not deter utilization for Part D.
